Check-Cap Ltd. (NASDAQ:CHEK) Short Interest Up 226.3% in May

Check-Cap Ltd. (NASDAQ:CHEK – Get Rating) was the recipient of a large growth in short interest during the month of May. As of May 15th, there was short interest totalling 50,900 shares, a growth of 226.3% from the April 30th total of 15,600 shares. Based on an average trading volume of 63,400 shares, the days-to-cover ratio is presently 0.8 days. Currently, 0.9% of the company’s stock are sold short.

Check-Cap Stock Down 0.7 %

Shares of NASDAQ:CHEK traded down $0.01 on Friday, reaching $1.46. 17,707 shares of the company’s stock were exchanged, compared to its average volume of 62,462. The firm has a market capitalization of $7.04 million and a price-to-earnings ratio of -0.65. Check-Cap has a fifty-two week low of $1.22 and a fifty-two week high of $9.20. The business’s 50-day moving average is $1.44 and its two-hundred day moving average is $2.70.

Check-Cap (NASDAQ:CHEK – Get Rating) last issued its earnings results on Friday, March 31st. The medical research company reported ($0.64) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.04. Analysts predict that Check-Cap will post -1.8 earnings per share for the current fiscal year.

Analysts Set New Price Targets

A number of research firms have commented on CHEK. StockNews.com began coverage on shares of Check-Cap in a research note on Friday. They set a “sell” rating on the stock. HC Wainwright reduced their price objective on shares of Check-Cap from $15.00 to $7.00 and set a “buy” rating on the stock in a research note on Wednesday, April 5th.

Institutional Trading of Check-Cap

A number of institutional investors and hedge funds have recently modified their holdings of CHEK. Citadel Advisors LLC increased its holdings in shares of Check-Cap by 51.2% in the 3rd quarter. Citadel Advisors LLC now owns 141,319 shares of the medical research company’s stock worth $41,000 after acquiring an additional 47,868 shares during the period. Susquehanna International Group LLP acquired a new stake in shares of Check-Cap in the 1st quarter worth about $57,000. Virtu Financial LLC increased its holdings in shares of Check-Cap by 363.4% in the 2nd quarter. Virtu Financial LLC now owns 224,696 shares of the medical research company’s stock worth $69,000 after acquiring an additional 176,207 shares during the period. Finally, Sabby Management LLC acquired a new stake in shares of Check-Cap in the 1st quarter worth about $91,000. 17.59% of the stock is owned by institutional investors and hedge funds.

Check-Cap Company Profile

(Get Rating)

Check-Cap Ltd. is a clinical stage medical diagnostics company, which engages in the development of ingestible imaging capsule system for colorectal cancer screening. Its patented technology, C-Scan, is a patient-friendly preparation-free test designed to detect polyps before they may transform into cancer.